- Works count
- 57
- Citation count
- 9,987
- H-index
- 18
- i10-index
- 23
Research interests
Publications
Perioperative Nivolumab in Resectable Lung Cancer
New England Journal of Medicine · 2024 · 10.1056/nejmoa2311926
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet Oncology · 2021 · 10.1016/s1470-2045(20)30641-0
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2019 · 10.1056/nejmoa1910231
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30634-5
Current projects
No projects listed.